India Pharmaceutical Market Overview Growing economic wealth fuels pharma market growth, but generics dominate

The prescription pharmaceutical market in India generated $7.1 billion in sales in 2009, with an annual growth rate of 18.1% between 2008 and 2009. Key growth drivers include India's growing economy, low operating costs, expanding health insurance coverage and healthcare expenditure especially among the middle classes. It is an overview of the Indian pharmaceutical market including socioeconomic trends, regulatory issues, market sizing, expiry analysis and drug infrastructure analysis

Scope
- Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property position in India
- Assesses the size of the Indian pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
- Examines the Indian generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
- Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis

Highlights
India's expanding and ageing population, together with its growing economic wealth are driving drug expenditure, a trend which is putting pressure on the government to provide better healthcare services a move which will further stimulate pharma market growth.

However, until government efforts to improve healthcare coverage for the poor are expanded, most drug expenditure will be derived from the upper and middle classes who are increasingly suffering from Western type of diseases and are turning towards foreign branded drugs.

Domestic manufacturers dominate the Indian pharmaceutical market, with generics accounting for over 99% of the total market volume and 20% of market value. Despite market saturation, uptake is and will continue to be driven primarily by the growing number of patients gaining access to affordable medicines, with branding critical for success.

Reasons to Purchase
- Evaluate the evolving regulatory landscape and the impact of expanding healthcare coverage on market access in India
- Quantify the size and growth of the prescription pharmaceutical market in India, analyzing key therapy areas, brands and companies
- Assess drivers and resistors of generic and biosimilars uptake in India
[Studien Infos ausblenden]

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2
1. India – Executive Summary 3
Introduction 3
Strategic scoping and focus 4
Key findings – healthcare drivers and resistors in India 5
Related reports 19
Upcoming related reports 19
2. India – Socio-demographic and economic analysis 22
India – Key findings 22
India – Demographic trends 24
India – Disease burden 31
India – Political climate 35
India – Economic climate 36
India – Business environment 41
3. India – Healthcare system and drug regulatory analysis 46
India – Key findings 46
India – Healthcare expenditure 49
India – Healthcare system 52
India – Health insurance 59
India – Regulatory issues 67
India – Pricing and Reimbursement 78
4. India – Prescription pharmaceutical sales analysis 81
India – Key findings 81
India – Pharmaceutical market size 82
India – Leading therapy areas 84
India – Leading prescription pharmaceutical brands 88
India – Leading pharmaceutical companies 92
5. India – Drug expiry analysis 100
India – Key findings 100
India – Generics market dynamics 102
India – Generics drivers and resistors in the domestic market 106
India – Key generics players in the domestic market 110
India – Generics drivers and resistors to the growth of domestic manufacturers globally 113
India – Key generics players in the global generics market 117
India – Small molecule brand erosion 119
India – Biosimilars market dynamics 121
6. India – Pharmaceutical Industry Infrastructure analysis 131
India – Key findings 131
India – Pharmaceutical industry infrastructure overview 132
India – Key company infrastructure 138
7. Bibliography 177
India – Socio-demographic and economic analysis 179
India – Healthcare systems and regulations 185
India – Prescription pharmaceutical sales 192
India – Drug expiry analysis 193
India – Pharmaceutical industry infrastructure analysis 198
APPENDIX 204
Exchange rates used in this report 204
Datamonitor prescription pharmaceutical definition and therapy area classification 205
About Datamonitor 206
Disclaimer 207
Disclaimer 208
[Inhaltsverzeichnis ausblenden]